Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the long-term safety and tolerability of ianalumab in adolescents and adults with systemic lupus erythematosus who have previously completed treatment in one of two core SIRIUS-SLE studies. This extension study focuses on participants with moderate-to-severe disease activity and positive anti-nuclear antibodies. The study is a phase 3, randomized, double-blind, placebo-controlled trial sponsored by Novartis Pharmaceuticals. The study involves three treatment periods over up to 7 years a 3-year double-blind phase where participants receive ianalumab subcutaneously either monthly or quarterly, or a monthly placebo followed by a 2-year period assessing safety and efficacy of treatment withdrawal and open-label monthly ianalumab and finally, an open-label safety monitoring period lasting up to 2 years. Participants receive the treatments subcutaneously as scheduled during each period. Participants will be closely monitored throughout the study, with assessments covering adverse events, disease activity responses, damage indices, corticosteroid use, and antibody levels. The primary measure is the number of treatment-emergent adverse events or serious adverse events up to about 324 weeks. Regular evaluations include clinical assessments, laboratory tests, and serum measurements. The total study duration for participants may extend up to 7 years, including long-term safety follow-up.
Actively Recruiting
This research aims to provide continued access to the drug anifrolumab for participants who have completed a previous clinical study and are assessed by the Investigator to still benefit from ongoing treatment. The study focuses on monitoring the long-term safety and tolerability of anifrolumab in people with conditions including Systemic Sclerosis, Cutaneous Lupus, Myopathies, and Systemic Lupus Erythematosus. Participants must have received at least one dose of anifrolumab in the prior study and be considered suitable to continue treatment. Participants will receive anifrolumab in the same form and manner as in the parent trial, which may be via pre-filled syringe, pre-filled pen, or infusion. This is an open-label study without randomization, where all participants continue on anifrolumab until they meet study discontinuation criteria. Those with treatment gaps or on compassionate use can also enroll. The study enrollment visit occurs at the end of the parent study after all safety follow-up assessments are complete. Throughout the study, safety monitoring includes collecting data on serious and non-serious adverse events from the first dose until 12 weeks after the last dose of anifrolumab. Participants will be followed until they discontinue, with ongoing assessments of tolerability. The study duration extends until December 2032, allowing long-term observation of treatment effects and safety.